GET DAILY SIGNALSCovista (CVSA) Posts Steady Q1 Growth with Revenue Up +10.7%
Key Takeaways
- Revenue reached $511.5 million, up 10.7% year over year and above the roughly $489 million consensus estimate.
- Adjusted earnings per share (EPS) came in at $2.19, comfortably ahead of the consensus estimate of about $1.83.
- Total enrollment rose 7.6% to 104,713 students, marking a 13th consecutive quarter of enrollment growth.
- Adjusted EBITDA climbed 17.1% to $131.2 million, with margin expanding to 25.6%.
- Management raised its full-year fiscal 2027 guidance for both revenue and adjusted EPS on the strength of the quarter.
- Shares edged higher in the immediate aftermath of the release as investors digested the beat-and-raise report.
Why This Quarter Matters
CVSA, America's largest healthcare educator, operates institutions including Chamberlain University, Walden University, and the Ross University schools across nursing, medicine, and veterinary disciplines. The company's fiscal year runs from July through June, meaning this report covers the first quarter of fiscal 2027, the three months ended in September 2026. Because enrollment trends drive future revenue, investors closely watch student counts alongside profitability. The quarter tested whether CVSA's multi-year expansion could continue amid changes to federal student loan programs, which shifted some enrollment timing between intake cycles. Strong results here signal durable demand for healthcare education and support the company's "Purpose at Scale" growth strategy. I also checked this using Tickeron's AI Screener to see how the stock compares to others in the industry.
The Numbers Behind the Report
CVSA reported first quarter fiscal 2027 revenue of $511.5 million, a 10.7% increase from the prior-year period and above Wall Street's consensus estimate of approximately $489.4 million. Growth was broad-based across all three segments, led by Walden and the Medical and Veterinary businesses, with Chamberlain contributing even as it invests in new campuses.
Adjusted EPS was $2.19, up 25.1% year over year and well above the consensus estimate of roughly $1.83. On a GAAP basis, net income was $67.4 million, or $1.95 per share. Adjusted net income rose 16.8% to $75.8 million, supported by a lower share count and reduced interest expense. Adjusted EBITDA increased 17.1% to $131.2 million, with an adjusted EBITDA margin of 25.6%, up 140 basis points from the prior year.
Total company enrollment grew 7.6% to 104,713 students. Management raised full-year fiscal 2027 revenue guidance to a range of $2.06 billion to $2.09 billion, up from a prior midpoint of $2.07 billion, and lifted adjusted EPS guidance to a range of $9.00 to $9.20, roughly $9.10 at the midpoint. One area to note: free cash flow margin came in at 14.9%, down from 24.8% a year earlier, reflecting continued investment in growth initiatives.
How the Market Responded
Shares of CVSA edged higher by roughly 1.2% in the immediate aftermath of the release, reflecting a broadly positive but measured response to a quarter that topped both revenue and profit expectations while raising full-year guidance. The muted magnitude of the move suggests investors had already priced in much of the company's momentum, though the enrollment durability and margin expansion offered reassurance about the quality of growth. Sentiment heading into the report had been supported by a streak of estimate beats, and the confirmation of a 13th consecutive quarter of enrollment growth reinforced confidence in the underlying demand story, even as attention turned to the modest decline in free cash flow margin.
What to Watch Going Forward
Following the beat-and-raise quarter, investors will likely focus on whether CVSA can sustain its enrollment trajectory through the remainder of fiscal 2027. Management noted that some students accelerated their start dates ahead of changes to federal loan programs, which shifted timing between the May and September intake cycles. As a result, the company emphasized that the two periods should be viewed together, and investors will be watching to confirm the blended trend remains healthy.
Margin expansion will be another key theme. The adjusted EBITDA margin improved 140 basis points, but free cash flow margin declined as the company funds strategic initiatives, including new Chamberlain campuses and enterprise technology investments such as an AI-powered classroom. Monitoring how these investments translate into enrollment efficiency and long-term profitability will be central to the narrative.
Partnerships with health systems such as Advocate Health and SSM Health also represent a growth lever, offering a more durable enrollment pipeline at a lower cost of acquisition. Finally, regulatory and policy developments around federal student loans and healthcare education funding remain important external factors that could influence student demand and, in turn, revenue and earnings over the coming quarters.
Enhancing My Research with Tickeron Tools
In my own workflow, Tickeron's AI Screener has become a practical way to quickly scan for stocks with similar fundamentals and technical setups in the education and healthcare services space. It lets me apply filters for enrollment-driven growth names and compare performance metrics without spending hours on manual reviews. This kind of targeted screening helps confirm whether a company's results stand out relative to peers before digging deeper into the details.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CVSA saw its Stochastic Oscillator recovers from the overbought zone
The Stochastic Oscillator for CVSA moved out of overbought territory on October 28, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 67 similar instances where the indicator exited the overbought zone. In 48 of the 67 cases the stock moved lower. This puts the odds of a downward move at 72%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CVSA as a result. In 55 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 66%.
CVSA moved below its 50-day moving average on October 28, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVSA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
CVSA broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CVSA's RSI Indicator exited the oversold zone, 16 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for CVSA just turned positive on October 02, 2026. Looking at past instances where CVSA's MACD turned positive, the stock continued to rise in 31 of 41 cases over the following month. The odds of a continued upward trend are 76%.
The 10-day moving average for CVSA crossed bullishly above the 50-day moving average on October 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.
Following a +3.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVSA advanced for three days, in 290 of 389 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 180 of 269 cases where CVSA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 34 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. CVSA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 51 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.977) is normal, around the industry mean (1.321). P/E Ratio (17.618) is within average values for comparable stocks, (9.729). Projected Growth (PEG Ratio) (0.866) is also within normal values, averaging (1.327). Dividend Yield (0.000) settles around the average of (3.433) among similar stocks. P/S Ratio (2.325) is also within normal values, averaging (27.566).
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of educational services
Industry OtherConsumerSpecialties
Advertisement